| Nome |
# |
|
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?, file e31e124d-b6eb-987f-e053-3705fe0a095a
|
987
|
|
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences., file e31e124d-7fae-987f-e053-3705fe0a095a
|
439
|
|
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going, file e31e124d-13b9-987f-e053-3705fe0a095a
|
400
|
|
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges, file 2070feea-fd64-4e63-a56f-c96909480f9e
|
374
|
|
Immune characterization of breast cancer metastases: prognostic implications., file e31e124d-5d08-987f-e053-3705fe0a095a
|
258
|
|
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer., file e31e124d-2167-987f-e053-3705fe0a095a
|
227
|
|
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience., file e31e124c-b4d4-987f-e053-3705fe0a095a
|
221
|
|
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients., file e31e124d-83c2-987f-e053-3705fe0a095a
|
212
|
|
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus, file e31e124d-734b-987f-e053-3705fe0a095a
|
191
|
|
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy, file e31e124e-9f47-987f-e053-3705fe0a095a
|
179
|
|
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era, file e31e124f-76f2-987f-e053-3705fe0a095a
|
172
|
|
The Role of Exosomes in Breast Cancer Diagnosis., file e31e124f-7c6a-987f-e053-3705fe0a095a
|
155
|
|
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications, file e31e124d-737e-987f-e053-3705fe0a095a
|
153
|
|
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe, file e31e124f-f589-987f-e053-3705fe0a095a
|
151
|
|
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy., file e31e124d-f9c8-987f-e053-3705fe0a095a
|
149
|
|
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study., file e31e124d-beb7-987f-e053-3705fe0a095a
|
142
|
|
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better?, file e31e124d-83c0-987f-e053-3705fe0a095a
|
140
|
|
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial, file e31e124d-cb10-987f-e053-3705fe0a095a
|
136
|
|
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e31e124d-c17d-987f-e053-3705fe0a095a
|
125
|
|
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review., file e31e124f-232b-987f-e053-3705fe0a095a
|
110
|
|
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word
experience., file e31e124d-2b94-987f-e053-3705fe0a095a
|
109
|
|
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer., file e31e124d-2a58-987f-e053-3705fe0a095a
|
93
|
|
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature., file e31e124e-211f-987f-e053-3705fe0a095a
|
91
|
|
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series., file e31e124f-6d6c-987f-e053-3705fe0a095a
|
91
|
|
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials., file e31e124f-d99a-987f-e053-3705fe0a095a
|
88
|
|
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?, file e31e124d-7d97-987f-e053-3705fe0a095a
|
81
|
|
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature, file e31e124f-eaba-987f-e053-3705fe0a095a
|
80
|
|
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer., file e31e124d-269e-987f-e053-3705fe0a095a
|
79
|
|
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus., file e31e124d-283e-987f-e053-3705fe0a095a
|
70
|
|
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status, file e31e124c-f954-987f-e053-3705fe0a095a
|
66
|
|
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis., file 9ee10f62-4b6b-4612-9f25-29a4451852aa
|
63
|
|
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status., file e31e124d-28b2-987f-e053-3705fe0a095a
|
57
|
|
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE, file e31e124e-772e-987f-e053-3705fe0a095a
|
53
|
|
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis, file e31e124f-f524-987f-e053-3705fe0a095a
|
52
|
|
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients, file e31e1250-9861-987f-e053-3705fe0a095a
|
49
|
|
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial, file e31e124d-cb13-987f-e053-3705fe0a095a
|
45
|
|
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy, file 1faffc70-b523-4d8b-b4f9-d9cc34f33630
|
42
|
|
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib, file 64682e8b-8100-404c-aab8-07162745638b
|
42
|
|
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer, file e31e124f-d998-987f-e053-3705fe0a095a
|
41
|
|
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis, file e31e124f-f522-987f-e053-3705fe0a095a
|
39
|
|
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases ., file e31e124d-83be-987f-e053-3705fe0a095a
|
36
|
|
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis., file e31e124e-e288-987f-e053-3705fe0a095a
|
34
|
|
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens, file e31e124f-a611-987f-e053-3705fe0a095a
|
33
|
|
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review., file 1507e16c-2218-4472-86fc-46938f88e71c
|
23
|
|
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients., file e31e124d-d296-987f-e053-3705fe0a095a
|
23
|
|
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC)., file e31e124d-d298-987f-e053-3705fe0a095a
|
21
|
|
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients ., file e31e124d-7fd5-987f-e053-3705fe0a095a
|
18
|
|
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center., file e31e124d-d05e-987f-e053-3705fe0a095a
|
15
|
|
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer., file d6cab42a-252e-4b2d-867a-2e237f1d02d3
|
14
|
|
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients., file 0a3040af-a1c5-49c5-a320-c46414b2b92e
|
8
|
|
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials, file 236df937-b400-4e8b-bda7-a84c5e43ef11
|
5
|
|
TDM-1 efficacy in trastuzumabpertuzumab
pre-treated HER2
positive metastatic breast cancer
patients: a meta-analysis, file a2a596be-f36a-45a2-a45c-8f36d43f2e16
|
5
|
|
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients, file e31e124c-048f-987f-e053-3705fe0a095a
|
5
|
|
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer, file 161dce2e-ee67-40e0-899d-82f74977ac1d
|
4
|
|
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file 921aaf66-5322-4cde-8cf6-e1b82a41538d
|
4
|
|
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact, file e31e124c-0494-987f-e053-3705fe0a095a
|
2
|
|
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis, file e31e124e-f3ca-987f-e053-3705fe0a095a
|
2
|
|
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis., file e31e124a-af9d-987f-e053-3705fe0a095a
|
1
|
|
Lapatinib and renal impairment: a case report, file e31e124b-3431-987f-e053-3705fe0a095a
|
1
|
|
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid., file e31e124c-aba0-987f-e053-3705fe0a095a
|
1
|
|
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients, file e31e124f-a8ef-987f-e053-3705fe0a095a
|
1
|
| Totale |
6.508 |
